Rodney Cusack
Senior Scientist at Race Oncology | Brisbane, Queensland, Australia
Rodney Cusack’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Rodney Cusack serves as a Senior Scientist at Race Oncology, a Phase 3 clinical biopharmaceutical company headquartered in Brisbane, Queensland, Australia, with a dedicated mission to advance cancer care. An alumnus of Queensland University of Technology, he applies his biotechnology expertise to evaluate and optimize novel therapeutic candidates within the organization. His technical work directly supports RCDS1, a small molecule agent that binds to G4-DNA and RNA to inhibit the MYC growth regulator while demonstrating potent therapeutic activity and a well-characterized safety profile.
BEST APPROACH TO REACH Rodney Cusack
Reach out through his verified personal email channel by delivering a targeted message outlining how your solutions or partnerships directly support RCDS1 clinical advancement or novel small-molecule oncology research.
Senior Scientist at Race Oncology in April 2024 - Present
Chief Executive Officer at Cytomatrix Pty Ltd in July 2023 - April 2024
CEO CARP Commercialisation at Cancer & Ageing Research Program (QUT) in February 2019 - December 2023
Director of Human Drug Development at QBiotics Group Limited in August 2011 - July 2018
Venture Consultant at Appetite Group in January 2010 - August 2011
Senior Research Officer at University of Queensland in August 2009 - July 2011
Owner and Director at LifeHaler in February 2010 - June 2011
Tutor at Queensland University of Technology in March 2010 - June 2010
Drug Development Manager at Bionomics Ltd in November 2006 - December 2007
Drug Development Manager at Xenome in March 2004 - October 2006
Research Officer at Xenome in July 2001 - February 2004
New Projects Officer at Alphapharm in June 1999 - June 2001
QUT (Queensland University of Technology), MBA, November 2026
The University of Queensland, PhD, November 1996 to November 2026
The University of Western Australia, BSc (Hons), November 1991 to November 1995
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients. Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.
Discover more about Race Oncology
VP Operations & Strategy (ASX: RAC) | Board Observer | HealthTech Co-Founder | Advisor | Keynote Speaker
Independent Consultant at Digital Health & Healthcare Transformation
(Oct 2022 – Present)
Scientific and Medical Affairs leader / MBA / High performance and longevity / Innovative commercialisation / Evidence generation / Patient and physician journey expert / Data driven strategist
At RACURA, we have a dedicated mission to be at the heart of cancer care. Our focus is on addressing the high unmet need of cancer patients for better and less damaging treatments that leverage the unique activity of our lead drug, RC220 bisantrene.
Experienced biotech executive
Amala Therapeutics is a biotech start-up focused on age-associated chronic health conditions with the hope of increasing healthspan and, ultimately, lifespan.
Vice President of Research at Racura Oncology
Vice President of Research at Racura Oncology
(Jul 2024 – Present)
Senior Scientist at Racura Oncology
Senior Scientist at Racura Oncology
(Feb 2025 – Present)
Team Leader I In Vivo Pharmacology I Preclinical Research I Drug Discovery I CRO Management I GLP I
Senior Scientist II - Preclinical Drug Development at Racura Oncology
(Jul 2024 – Present)
What is Rodney Cusack email address?
Email Rodney Cusack at [email protected] and [email protected]. This email is the most updated Rodney Cusack's email found in 2026.
What is Rodney Cusack phone number?
Rodney Cusack phone number is 2404810038.
How to contact Rodney Cusack?
To contact Rodney Cusack send an email to [email protected] or [email protected]. If you want to call Rodney Cusack try calling on 2404810038. (updated on December 07, 2025)
What company does Rodney Cusack work for?
Rodney Cusack works for Race Oncology.
What is Rodney Cusack's role at Race Oncology?
Rodney Cusack is Senior Scientist
What industry does Rodney Cusack work in?
Rodney Cusack works in the Biotechnology industry.
